rs10516487 — BANK1 R61H

BANK1 scaffold protein missense variant that shifts B-cell receptor signaling toward hyperactivation, increasing risk for systemic lupus erythematosus and other B-cell-driven autoimmune diseases

See your personal result for BANK1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

BANK1 R61H — The B-Cell Scaffold That Tilts Toward Autoimmunity

Every time your B cells encounter an antigen, a cascade of molecular events must balance signal amplification against self-tolerance. BANK1 (B-cell scaffold protein with ankyrin repeats 1) sits at the hub of this balance, acting as a scaffold that coordinates calcium signaling11 scaffold that coordinates calcium signaling
BANK1 promotes tyrosine phosphorylation of IP3 receptors (IP3R-1 and IP3R-2) via LYN kinase, mobilizing calcium from the endoplasmic reticulum to amplify B-cell receptor activation downstream of the B-cell receptor (BCR). The R61H variant — a single amino acid change from arginine to histidine at position 61 — does not simply abolish BANK1 function. It subtly shifts the balance: the G allele (encoding arginine) promotes a form of BANK1 that drives stronger, more sustained B-cell activation, while the A allele (encoding histidine) is associated with protection against autoimmune disease.

The Mechanism

The rs10516487 G>A substitution has a dual molecular effect22 dual molecular effect
Kozyrev et al. demonstrated rs10516487 affects both BANK1 mRNA splicing efficiency and the multimerization properties of the resulting protein. First, the protective A allele creates a stronger exonic splicing enhancer site for the SRp40 splicing factor, shifting the isoform balance toward the full-length BANK1 form (which retains exon 2) relative to the G risk allele — both alleles produce some full-length protein, but the A allele produces proportionally more. Second, the full-length protein containing the R61 residue (G allele) forms larger scaffold complexes33 larger scaffold complexes
The R61-containing isoform has increased potential for multimerization compared with the protective BANK1-H61 variant, forming larger cytoplasmic aggregates than the H61 (A allele) variant. The net effect of the G allele is dominated by the R61 protein's greater scaffolding capacity, driving stronger B-cell activation.

BANK1 directly interacts with BLK (B lymphoid tyrosine kinase), a Src-family kinase critical for BCR signaling. Co-immunoprecipitation studies44 Co-immunoprecipitation studies
Physical and genetic interaction between BANK1 and BLK confirmed in primary naive B cells; binding enhanced upon BCR stimulation with anti-IgM antibodies demonstrate that BANK1 and BLK bind directly, and this interaction is enhanced upon BCR stimulation. BANK1 also connects PLCγ2 (the enzyme generating the second messenger IP3) to the IP3 receptor. The net result of excess full-length BANK1 scaffold complexes is altered B-cell receptor signaling55 altered B-cell receptor signaling
BANK1 risk variants associated with decreased BCR-induced AKT activation and expanded memory B-cell populations in human B cells and dysregulated downstream signaling — the molecular signature of B-cell dysfunction.

The Evidence

BANK1 was identified as an SLE susceptibility gene in a genome-wide association study by Kozyrev et al.66 genome-wide association study by Kozyrev et al.
GWAS using 85,042 SNPs identified BANK1 R61H with combined P=3.7×10⁻¹⁰ and OR=1.38 across four independent case-control replication cohorts. The protective effect of the A allele was replicated in European and African American populations77 replicated in European and African American populations
Protective OR=0.64 (95% CI 0.49–0.85) in Caucasians and OR=0.75 (95% CI 0.55–1.03) in African Americans; minor allele frequency 31.2% in Caucasian controls vs. 22.6% in cases, confirming the association across ancestries. In Caucasian controls, the A allele frequency is approximately 30%, making heterozygosity common.

Beyond SLE, the G allele is associated with diffuse cutaneous systemic sclerosis88 diffuse cutaneous systemic sclerosis
Pooled OR=1.20 (95% CI 1.05–1.37, P=0.005) for diffuse SSc across six Caucasian cohorts totaling 2,380 patients and 3,270 controls, particularly in patients carrying anti-topoisomerase I antibodies. In primary Sjögren's syndrome99 primary Sjögren's syndrome
BANK1 rs10516487G/A associated with arthritis and keratoconjunctivitis sicca; BANK1-BLK genotype interaction showed OR=2.36, P<0.0001, the variant is associated with joint disease and dry-eye manifestations. BANK1 and BLK variants show significant gene-gene interaction1010 significant gene-gene interaction
Gene-gene interaction between BLK and BANK1 confirmed via logistic regression (P=0.013), multifactor dimensionality reduction (P<0.0001), and linear regression (P=0.0017) in SLE susceptibility — each gene's effect is amplified when risk variants of both are present.

Practical Actions

Carrying the GG or AG genotype means your B-cell signaling machinery has a subtle pro-activation bias. This does not cause autoimmune disease by itself — environmental triggers, other genetic variants (particularly HLA haplotypes and BLK alleles), and immune system stressors determine whether the genetic predisposition manifests. The most actionable implications are: monitoring for early autoimmune signs across the BANK1-associated spectrum (lupus, systemic sclerosis, Sjögren's syndrome), awareness of belimumab (Benlysta) as a highly relevant therapeutic option if SLE does develop given its direct relevance to the BANK1 pathway, and attention to gut microbiome health, which recent evidence suggests modulates BANK1-driven autoimmunity.

Belimumab (Benlysta) targets BLyS/BAFF, a cytokine that promotes B-cell survival within the same signaling cascade that BANK1 R61H amplifies. Single-cell RNA sequencing in belimumab-treated SLE patients1111 Single-cell RNA sequencing in belimumab-treated SLE patients
Single-cell transcriptomic analysis of B-cell subsets during belimumab treatment suggests that belimumab modulates B-cell development pathway genes in treated B cells, which may include the BANK1 signaling axis. Carriers of the GG genotype who develop SLE should be aware of this mechanistic alignment when discussing treatment options.

Interactions

BANK1 R61H shows documented genetic and physical interaction with BLK (B lymphoid tyrosine kinase). Risk variants of both genes co-occur more often in SLE patients, and the combined effect exceeds what either gene contributes alone. In primary Sjögren's syndrome, the BANK1 × BLK interaction yielded OR=2.36 (P<0.0001), suggesting that the two proteins function as a unit — BANK1 as the scaffold and BLK as the kinase — within the BCR signaling complex.

The BLK locus (chromosome 8p23, tagged by rs13277113 and the C8orf13-BLK promoter region) independently reduces BLK expression, while BANK1 R61H amplifies the scaffold signaling. Together, they create compounding B-cell hyperactivation risk that is greater than either alone. This interaction is documented in SLE (rs7574865 in STAT4 is a separate lupus pathway variant) and extends to Sjögren's syndrome.

Recent mouse data1212 Recent mouse data
Bank1-deficient lupus-prone mice showed reduced gut permeability, altered claudin-1 distribution, and enrichment of Parabacteroides distasonis in the gut microbiome; oral administration of P. distasonis reduced disease severity in lupus mice demonstrates that BANK1 influences gut immune homeostasis through intestinal IgA production and IL-10-secreting B-cell differentiation in Peyer's patches. This places BANK1 at the interface of systemic B-cell autoimmunity and gut microbiome regulation — the core rationale for its placement in the immune-gut category.

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Variant Beneficial

Two copies of the protective A allele — reduced SLE and autoimmune disease risk

You carry two copies of the histidine-encoding A allele at BANK1 position 61. This is the protective genotype: the H61 protein forms smaller scaffold complexes with lower multimerization capacity, producing less amplified B-cell receptor signaling compared with the G allele. Your BANK1-mediated contribution to B-cell activation is below the population average, which is associated with reduced risk for SLE and related B-cell-driven autoimmune conditions. About 4–5% of European-ancestry individuals share this genotype. Your autoimmune risk from other variants (particularly HLA loci and BLK) is unaffected by BANK1 R61H.

AG Intermediate Risk Intermediate

One copy of the risk G allele — moderately elevated B-cell activation and autoimmune risk

You carry one copy of the arginine-encoding G allele. Heterozygotes produce a mixture of full-length (R61) and shorter (H61) BANK1 protein, creating intermediate BCR signaling amplification. Studies in Europeans show the A allele frequency in SLE cases is approximately 22–23% versus 28–31% in healthy controls, indicating the G allele provides a modest but consistent risk increment. Your odds ratio for SLE is approximately 1.2–1.4 relative to AA homozygotes. About 34% of the general population carries this heterozygous genotype.

GG Elevated Risk High Risk

Two copies of the risk G allele — substantially elevated B-cell hyperactivation and SLE risk

You carry two copies of the arginine-encoding G allele, the full-risk genotype. Your BANK1 protein predominantly adopts the R61 form, which generates larger cytoplasmic scaffold complexes and altered downstream BCR signaling — including decreased AKT activation — compared to AA or AG individuals. Population studies show the minor allele (A) frequency in cases versus controls differs most dramatically in the GG vs. AA comparison. The original GWAS reported an overall OR of 1.38 across heterozygotes and homozygotes combined; GG homozygotes carry the highest BANK1-attributable risk. About 60% of the general population carries this genotype, making it the most common state — but the compounding effect with BLK variants and HLA haplotypes is where substantial individual risk emerges.